Cowen Healthcare Royalty Partners, a healthcare investment firm based in Stamford, Conn., has closed it second fund with roughly $1 billion in capital commitments — more than 75 percent of its initial target, according to the firm. Similar to its first fund, Cowen Royalty will target investments between $20 million and $100 million in the U.S., Europe and Asia.
Cowen Healthcare Royalty Partners (Cowen Royalty), a global healthcare investment firm, today announced the closing of Cowen Healthcare Royalty Partners II, L.P. (CHRP II). With approximately $1 billion in new capital commitments, Cowen Royalty will sustain its broad strategy of investing in traditional passive royalties, Synthetic royalties® and structured financings. Cowen Royalty exceeded the initial target for CHRP II by more than 75 percent.
“With a large amount of fresh capital and a healthy pipeline of financing opportunities and royalty asset sales, we believe we are well positioned to capitalize on this growing multi-billion dollar market opportunity,” commented Clarke B. Futch, Founding Managing Director at Cowen Royalty.
Similar to its first fund, Cowen Royalty will target investments between $20MM-$100MM in the U.S., Europe and Asia. The two main categories for capital investments include commercial stage biopharmaceutical and medical device companies in need of growth capital, and universities/inventors looking to monetize product interests.
“Increased demand for alternatives to traditional debt or equity by both companies and royalty owners will continue to drive this finance category going forward,” further commented Cowen Royalty Founding Managing Director Todd C. Davis.
Since raising CHRP I in 2008, Cowen Royalty has made a total of 20 investments in 17 products including Lexiva® (GlaxoSmithKline), Cetrotide® (Merck Serono), Myozyme® (Genzyme, a Sanofi Company), Qutenza® (Astellas Pharma), Oracea® (Galderma) and KAMRA® inlay (AcuFocus). During the second half of 2011, Cowen Royalty closed eight (8) deals including product focused investments with Dyax Corp (DYAX), Stereotaxis, Inc. (STXS) and Zogenix (ZGNX), and royalty monetizations with several universities. The Firm has continued to strengthen its team, adding experienced investment, financial, legal and operations professionals under the leadership of co-founders Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch.
In addition to existing Cowen Royalty limited partners, CHRP II LP’s consist of a world-class list of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.
Credit Suisse Securities (USA) LLC acted as exclusive financial advisor/placement agent and Goodwin Procter LLP as legal counsel.
About Cowen Healthcare Royalty Partners
Founded in 2007, Cowen Healthcare Royalty Partners is a global healthcare investment firm with over $1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry. For more information, visit www.cowenroyalty.com.